CHU Jean Minjoz
CHU Jean Minjoz
Besançon, France4 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years | Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cryptogenic Ischemic Stroke, atrial septal defect, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, congenital heart disease, heart disorder, heart septal defect, ischemic stroke, nervous system disorder, patent foramen ovale, stroke disorder, vascular disorder | Recruiting | Phase 3 | 2026-03-24 | NCT05387954 | |
| Developmental and Epileptic Encephalopathies Diagnosed Via Long-read Genome Sequencing | Drug Resistant Epilepsy, brain disorder, central nervous system disorder, developmental and epileptic encephalopathy, epilepsy, nervous system disorder | Not yet recruiting | Not stated | 2026-02-09 | NCT07396883 | |
| Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Nutritional and Metabolic Diseases, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, dihydropyrimidine dehydrogenase deficiency, hereditary disease, inborn disorder of purine or pyrimidine metabolism, inborn errors of metabolism, intestinal disorder, metabolic disease, neoplasm, rectal disorder | Recruiting | Phase 2 | 2025-12-10 | NCT06245356 | |
| Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Phase 1 / Phase 2 | 2025-05-30 | NCT05201352 |